<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article10</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/IMPROVE-IT" style="display:block; margin-bottom:10px;">IMPROVE-IT Original</a></li>
<h2><strong>IMPROVE-IT</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes". The New England Journal of Medicine. 2015. 372:2387-2397. PubMed • Full text • PDF <br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
Does the addition of ezetimibe to statin therapy in patients with a recent acute coronary syndrome reduce the rate of cardiovascular events?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
In patients with recent acute coronary syndrome and LDL cholesterol levels within guideline recommendations, the addition of ezetimibe to statin therapy resulted in incremental lowering of LDL cholesterol and a further reduction in the risk of cardiovascular events without significant safety concerns.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/><br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
At the time of patient enrollment, guidelines recommended LDL cholesterol levels of less than 70 mg per deciliter for patients post-acute coronary syndrome. These current findings suggest additional benefits with even lower LDL cholesterol levels.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
Double-blind, randomized control trial with median follow-up of 6 years.<br/>
<h2><strong>Population</strong></h2><br/>
18,144 patients, ≥50 years old, hospitalized within preceeding 10 days for acute coronary syndrome and with LDL cholesterol levels of 50-125 mg per deciliter (or 50-100 mg per deciliter if already on lipid-lowering therapy).<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
- Simvastatin (40 mg) + Ezetimibe (10 mg) [simvastatin–ezetimibe group]<br/>
- Simvastatin (40 mg) + Placebo [simvastatin-monotherapy group]<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
Primary Outcome:<br/>
- Composite of cardiovascular death, major coronary event, or nonfatal stroke<br/>
Secondary Outcomes:<br/>
- Composite of death from any cause, major coronary event, or nonfatal stroke<br/>
- Composite of death from coronary heart disease, nonfatal myocardial infarction, or urgent coronary revascularization ≥30 days after randomization<br/>
- Composite of death from cardiovascular causes, nonfatal myocardial infarction, hospitalization for unstable angina, all revascularization ≥30 days after randomization, or nonfatal stroke<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
- Study only included patients with acute coronary syndrome; results are most applicable to this population.<br/>
- Study statin regimen may not represent contemporary high-intensity statin therapy, as only simvastatin 40 mg and 80 mg were used.<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
Merck (the sponsor and manufacturer of ezetimibe).<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
- Cholesterol Treatment Trialists (CTT) Collaborators. Am J Cardiol. 2014.<br/>
- Sabatine MS, et al. N Engl J Med. 2015.
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
